Pfizer sold $7.8B in COVID-19 vaccines last quarter

Pfizer said July 28 that it sold $7.8 billion in COVID-19 vaccines in the second quarter of this fiscal year, CNBC reported. 

The drugmaker raised its 2021 sales forecast for the shot to $33.5 billion, up from $26 billion. 

Pfizer expects an adjusted pretax profit in the high 20 percent range of revenue for the shot, CNBC reported. It expects full-year earnings between $3.95 and $4.05 per share, up from its previous estimate of $3.55 to $3.65 per share. 

"The second quarter was remarkable in a number of ways," Pfizer CEO Albert Bourla said in a statement, according to CNBC. "Most visibly, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented, with now more than a billion doses of BNT162b2 having been delivered globally."

Pfizer said it could file for emergency use authorization for a booster dose as early as August, CNBC reported. The drugmaker said it expects full approval for its vaccine by January. 

Read the full article here

 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars